Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1990 4
1991 2
1992 2
1993 1
1994 4
1995 1
1996 2
1997 8
1998 5
1999 6
2000 4
2001 5
2002 6
2003 9
2004 11
2005 14
2006 5
2007 6
2008 12
2009 14
2010 8
2011 11
2012 10
2013 15
2014 12
2015 20
2016 19
2017 14
2018 12
2019 14
2020 3
Text availability
Article attribute
Article type
Publication date

Search Results

235 results
Results by year
Filters applied: . Clear all
Page 1
TOX is a critical regulator of tumour-specific T cell differentiation.
Scott AC, Dündar F, Zumbo P, Chandran SS, Klebanoff CA, Shakiba M, Trivedi P, Menocal L, Appleby H, Camara S, Zamarin D, Walther T, Snyder A, Femia MR, Comen EA, Wen HY, Hellmann MD, Anandasabapathy N, Liu Y, Altorki NK, Lauer P, Levy O, Glickman MS, Kaye J, Betel D, Philip M, Schietinger A. Scott AC, et al. Among authors: altorki nk. Nature. 2019 Jul;571(7764):270-274. doi: 10.1038/s41586-019-1324-y. Epub 2019 Jun 17. Nature. 2019. PMID: 31207604
The lung microenvironment: an important regulator of tumour growth and metastasis.
Altorki NK, Markowitz GJ, Gao D, Port JL, Saxena A, Stiles B, McGraw T, Mittal V. Altorki NK, et al. Nat Rev Cancer. 2019 Jan;19(1):9-31. doi: 10.1038/s41568-018-0081-9. Nat Rev Cancer. 2019. PMID: 30532012 Free PMC article. Review.
Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance.
Fischer KR, Durrans A, Lee S, Sheng J, Li F, Wong ST, Choi H, El Rayes T, Ryu S, Troeger J, Schwabe RF, Vahdat LT, Altorki NK, Mittal V, Gao D. Fischer KR, et al. Among authors: altorki nk. Nature. 2015 Nov 26;527(7579):472-6. doi: 10.1038/nature15748. Epub 2015 Nov 11. Nature. 2015. PMID: 26560033 Free PMC article.
Tumour exosomal CEMIP protein promotes cancer cell colonization in brain metastasis.
Rodrigues G, Hoshino A, Kenific CM, Matei IR, Steiner L, Freitas D, Kim HS, Oxley PR, Scandariato I, Casanova-Salas I, Dai J, Badwe CR, Gril B, Tešić Mark M, Dill BD, Molina H, Zhang H, Benito-Martin A, Bojmar L, Ararso Y, Offer K, LaPlant Q, Buehring W, Wang H, Jiang X, Lu TM, Liu Y, Sabari JK, Shin SJ, Narula N, Ginter PS, Rajasekhar VK, Healey JH, Meylan E, Costa-Silva B, Wang SE, Rafii S, Altorki NK, Rudin CM, Jones DR, Steeg PS, Peinado H, Ghajar CM, Bromberg J, de Sousa M, Pisapia D, Lyden D. Rodrigues G, et al. Among authors: altorki nk. Nat Cell Biol. 2019 Nov;21(11):1403-1412. doi: 10.1038/s41556-019-0404-4. Epub 2019 Nov 4. Nat Cell Biol. 2019. PMID: 31685984 Free PMC article.
The Microenvironment of Lung Cancer and Therapeutic Implications.
Mittal V, El Rayes T, Narula N, McGraw TE, Altorki NK, Barcellos-Hoff MH. Mittal V, et al. Among authors: altorki nk. Adv Exp Med Biol. 2016;890:75-110. doi: 10.1007/978-3-319-24932-2_5. Adv Exp Med Biol. 2016. PMID: 26703800 Review.
The non-small cell lung cancer immune contexture. A major determinant of tumor characteristics and patient outcome.
Remark R, Becker C, Gomez JE, Damotte D, Dieu-Nosjean MC, Sautès-Fridman C, Fridman WH, Powell CA, Altorki NK, Merad M, Gnjatic S. Remark R, et al. Among authors: altorki nk. Am J Respir Crit Care Med. 2015 Feb 15;191(4):377-90. doi: 10.1164/rccm.201409-1671PP. Am J Respir Crit Care Med. 2015. PMID: 25369536 Free PMC article. Review.
Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial.
Kelly K, Altorki NK, Eberhardt WE, O'Brien ME, Spigel DR, Crinò L, Tsai CM, Kim JH, Cho EK, Hoffman PC, Orlov SV, Serwatowski P, Wang J, Foley MA, Horan JD, Shepherd FA. Kelly K, et al. Among authors: altorki nk. J Clin Oncol. 2015 Dec 1;33(34):4007-14. doi: 10.1200/JCO.2015.61.8918. Epub 2015 Aug 31. J Clin Oncol. 2015. PMID: 26324372 Clinical Trial.
Perioperative mortality and morbidity after sublobar versus lobar resection for early-stage non-small-cell lung cancer: post-hoc analysis of an international, randomised, phase 3 trial (CALGB/Alliance 140503).
Altorki NK, Wang X, Wigle D, Gu L, Darling G, Ashrafi AS, Landrenau R, Miller D, Liberman M, Jones DR, Keenan R, Conti M, Wright G, Veit LJ, Ramalingam SS, Kamel M, Pass HI, Mitchell JD, Stinchcombe T, Vokes E, Kohman LJ. Altorki NK, et al. Lancet Respir Med. 2018 Dec;6(12):915-924. doi: 10.1016/S2213-2600(18)30411-9. Epub 2018 Nov 12. Lancet Respir Med. 2018. PMID: 30442588 Free PMC article. Clinical Trial.
Immune reprogramming via PD-1 inhibition enhances early-stage lung cancer survival.
Markowitz GJ, Havel LS, Crowley MJ, Ban Y, Lee SB, Thalappillil JS, Narula N, Bhinder B, Elemento O, Wong ST, Gao D, Altorki NK, Mittal V. Markowitz GJ, et al. Among authors: altorki nk. JCI Insight. 2018 Jul 12;3(13):e96836. doi: 10.1172/jci.insight.96836. JCI Insight. 2018. PMID: 29997286 Free PMC article.
Screening for Lung Cancer.
Stiles BM, Pua B, Altorki NK. Stiles BM, et al. Among authors: altorki nk. Surg Oncol Clin N Am. 2016 Jul;25(3):469-79. doi: 10.1016/j.soc.2016.02.002. Surg Oncol Clin N Am. 2016. PMID: 27261909 Review.
235 results
Jump to page
Feedback